
Rocket Pharmaceuticals, Inc.: updates and filings
Price
$1.95
November 20, 2026Market cap $212M
What Ploutos Investor adds for Rocket Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 8, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 6, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosureForm8-K
- Sep 15, 2026Regulation FD disclosureForm8-K
- Sep 2, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Aug 27, 2026Officer or director changeForm8-K
- Aug 10, 2026Results of operationsForm8-K
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Regulation FD disclosureForm8-K
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 14, 2026Shares registered for employeesFormS-8
- Jun 30, 2026Officer or director changeForm8-K
- Jun 12, 2026Acquisition or disposal of assets, Regulation FD disclosureForm8-K
- May 28, 2026Filing (amendment)FormSC TO-I/A
- May 21, 2026Shareholder voteForm8-K
- May 7, 2026Results of operationsForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 28, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Apr 27, 2026FilingFormSC TO-I
- Apr 6, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 6, 2026Additional annual meeting materialFormDEFA14A
- Apr 6, 2026Annual meeting proxy statementFormDEF 14A
- Apr 3, 2026FilingFormSC TO-C
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 6, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosure | Document |
| Sep 15, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 2, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Aug 27, 2026 | 8-K | Officer or director change | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 14, 2026 | S-8 | Shares registered for employees | Document |
| Jun 30, 2026 | 8-K | Officer or director change | Document |
| Jun 12, 2026 | 8-K | Acquisition or disposal of assets, Regulation FD disclosure | Document |
| May 28, 2026 | SC TO-I/A | Filing (amendment) | Document |
| May 21, 2026 | 8-K | Shareholder vote | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 28, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Apr 27, 2026 | SC TO-I | Filing | Document |
| Apr 6, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 6, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 6, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 3, 2026 | SC TO-C | Filing | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 25, 2004.
The full analysis
What do Rocket Pharmaceuticals's filings show?
The filings are where every one of Rocket Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.